Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin crossover study on microvascular circulation in type 2 diabetes
2014-003053-34Phase 3Completed
- Sponsor
- IPPMed
- Start
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of empagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by IPPMed. Primary endpoints: Effect of empagliflozin on pulse wave reflection parameters in the arterial tree, Central aortic systolic pressure and 4 more. Started Nov 2014; status: completed.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2014-003053-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003053-34.